Chemical Name: (1S,2S,3S)-3-(2-hydroxyethoxy)-5-((3-((3aS,4S,6S,6aR)-6-(2-hydroxyethoxy)-2,2-dimethyltetrahydro-4H-cyclopenta[d][1,3]dioxol-4-yl)-5-(propylthio)-3H-[1,2,3]triazolo[4,5-d]pyrimidin-7-yl)amino)cyclopentane-1,2-diol
Smiles: OCCO[C@H]([C@@H]1[C@H]2OC(C)(C)O1)C[C@H]2N(N=N3)C4=C3C(NC5C[C@H](OCCO)[C@@H](O)[C@H]5O)=NC(SCCC)=N4
Inchi: InChI=1S/C9H9F2N.C8H8O3/c10-7-3-1-2-5(9(7)11)6-4-8(6)12;9-7(8(10)11)6-4-2-1-3-5-6/h1-3,6,8H,4,12H2;1-5,7,9H,(H,10,11)/t6-,8+;/m0./s1
Estimation Of Ticagrelor In Commercial Dosage Form Using A Sensitive Validated RP-HPLC Method
By Madhuri, K.; Rao, Y. Srinivasa; Varaprasada, Rao K.; Deepthi, R.
From World Journal of Pharmaceutical Research (2021), 10(6), 1281-1292.
Development and validation of stability indicating RP-HPLC method for the estimation of Ticagrelor by forced degradation studies
By Dole, Manjusha; Kendre, Meenakshi; Wagh, Viplav
From World Journal of Pharmacy and Pharmaceutical Sciences (2019), 8(5), 711-724
Development of a validated HPLC-PDA method for stability indicating study of ticagrelor: a novel anti-platelet agent (P2Y12-ADP receptor blocker)
By Sulthana, Shabana; Anuradha, V.; Rao, Mandava V. Basaveswara
From International Journal of Pharmaceutical, Chemical and Biological Sciences (2017), 7(1), 36-42